Current Trial Report: A Multicenter Phase I/Ib study of Capmatinib Plus Trametinib in Patients With Metastatic Nonsmall Cell Lung Center Harboring MET Exon 14 Skipping Mutations and Other MET-Alterations.

Lara, Matthew S; Riess, Jonathan W; Goldman, Jonathan W; Jiang, Fei; Bivona, Trever G; Blakely, Collin M

Lara, Matthew S; Riess, Jonathan W; Goldman, Jonathan W; Jiang, Fei; Bivona, Trever G; Blakely, Collin M.

Afiliação

Lara MS; University of California Davis Comprehensive Cancer Center, Sacramento CA, USA.
Riess JW; University of California Davis Comprehensive Cancer Center, Sacramento CA, USA.
Goldman JW; University of California Los Angeles, Los Angeles, CA, USA.
Jiang F; University of California San Francisco Helen Diller Comprehensive Cancer Center, San Francisco, CA, USA.
Bivona TG; University of California San Francisco Helen Diller Comprehensive Cancer Center, San Francisco, CA, USA.
Blakely CM; University of California San Francisco Helen Diller Comprehensive Cancer Center, San Francisco, CA, USA. Electronic address: Collin.Blakely@ucsf.edu.

Clin Lung Cancer ; 2024 Jul 05.

Article em En | MEDLINE | ID: mdl-39089913

Palavras-chave

Capmatinib; MAPK signaling; MET exon skipping mutation; Non-small cell lung cancer; Trametinib

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Clin Lung Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google